Skip to main content

Evonik expands in pharma in Germany

Evonik, which is one of the world’s largest pharmaceutical CDMOs, has announced the €25 million first stage of a long-term programme to expand API and advanced intermediates capacity at its sites in Dossenheim and Hanau, Germany. This should be completed by mid-2021 and the whole project should be finalised prior to 2024.

AGC expands Spanish site

AGC has announced plans to expand its CDMO subsidiary, AGC Pharma Chemicals Europe. As well as adding 30% to the capacity of its production facilities by May 2022, this will see the addition of a new micronisation facility and a new R&D facility, which is due to begin operation in March 2021. The plant, near Barcelona, was originally known as Malgrat Pharma Chemicals.

Evotec in ‘Pan-TB’ collaboration

Drug discovery firm Evotec, owner of the API manufacturer Aptuit, is a member of the Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration, which was launched formally on 27 February. This will aim to transform global action on TB, which causes more deaths than any other infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018.

Sanofi to establish API player

Big Pharma giant Sanofi has announced plans to create a stand-alone company dedicated to the production and marketing of APIs to third parties.

Lonza swings to pharma

Lonza has announced results for 2019, in which its growth was entirely driven by the Pharma Biotech & Nutrition division on which it will base its future.

Porton opens fermentation lab

Porton Pharma Solutions, a Chinese custom API services firm, has officially put into use its fermentation pilot laboratory at Chongqing, Sichuan province.
Subscribe to Pharmaceuticals

 

 

 

AMRI banner advert